Tumor type | Number of tumors | Method | Result | Reference |
---|---|---|---|---|
colorectal cancer | 78 | immunohistochemistry | expression in tumors higher than in normal tissues | [8] |
significant correlations with invasion and Duke’s stage | ||||
advanced rectal cancer | 76 | immunohistochemistry | significant correlations with tumor regression | [9] |
20 | mRNA microarray | and long-term clinical outcome | ||
colorectal carcinoma | 56 | immunohistochemistry | expression in tumors higher than in normal tissues | [10] |
significant correlations with Duke’s stage, tumor size, | ||||
invasion, and lymph node metastasis | ||||
gastric adenocarcinoma | 208 | immunohistochemistry | expression in tumors higher than in normal tissues | [11] |
RT-PCR | ||||
gastric adenocarcinoma | 160 | immunohistochemistry | prognostic factor for poor survival time | [12] |
RT-PCR | ||||
gastric adenocarcinoma | 135 | immunohistochemistry | expression in tumors higher than in normal tissues | [13] |
significant correlations with stage, nodal status and diffuse | ||||
growth pattern, no correlation to lymph node metastasis | ||||
hepatocellular carcinoma | 135 | immunohistochemistry | expression in tumors higher than in normal tissues, | [14] |
111 | RT-PCR | significant correlations to venous invasion, tumor nodules | ||
and Edmondson grade, prognostic factor for poor survival time | ||||
hepatoblastoma | 74 | RT-PCR | expression in tumors higher than in normal tissues | [15] |
non-small cell lung | 100 | immunohistochemistry | expression in tumors higher than in normal tissues | [16] |
cancer | significant correlations with stage, grade and lymph | |||
node metastasis | ||||
melanoma | 36 | significant correlation with metastasis | ||
astrocytic tumors | immunohistochemistry | significant correlation with grade of anaplasia | [17] | |
non-Hodgkin lymphoma | 66 | immunohistochemistry | prognostic factor for poor survival time | [18] |
non-Hodgkin lymphoma | 118 | immunohistochemistry | significant correlations with grade, | |
prognostic factor for poor survival time | ||||
cutaneous T-cell | 49 | immunohistochemistry | expression in tumors higher than in patch and | [19] |
lymphoma | plaque-stage lesions | |||
muliple myeloma | 188 | immunohistochemistry | prognostic factor for poor survival time | [20] |
breast carcinoma | 135 | immunohistochemistry | expression in tumors higher than in normal tissues | [21] |
no correlation with 10 year survival time | ||||
breast carcinoma | 3093 | immunohistochemistry | no correlation with 10 year survival time | [22] |
ovarian tumors | 17 | immunohistochemistry | significant correlation with grade | [23] |
ovarian tumors | 107 | immunohistochemistry | expression in high malignant tumors than in low | [24] |
malignant tumors, prognostic factor for poor survival time | ||||
endometrial tumors | 20 | immunohistochemistry | significant correlation with grade | [25] |
cervical carcinoma | 36 | immunohistochemistry | significant correlation with tumor size | [26] |